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Abstract. Ewing's sarcoma is the second most common 
primary sacral tumor. Ewing's sarcomas are rare, aggressive 
tumors with a tendency towards recurrence following resection 
and early metastasis. Although peak incidences are between 
the ages of 10 and 20 years, patients of younger or older age 
account for almost 30% of the cases. We report the case of 
a 52-year-old healthy female who presented with a 2-week 
history of pain in her right posterior thigh that was unable to 
be relieved by non‑steroidal anti‑inflammatory medicine and 
physical therapy. Magnetic resonance imaging demonstrated an 
irregular right presacral mass and core needle biopsy revealed 
a small, round blue cell neoplasm. Staging workup was normal 
and an open biopsy was positive for the ES translocation 
(22q12). The patient was treated with 17 cycles of vincristine, 
adriamycin and cytoxan with mesna rescue, alternating with 
ifosfamide and etoposide in addition to external beam radia-
tion. Post-treatment imaging demonstrated complete resolution 
of the tumor. Six weeks post-treatment the patient presented 
with a recurrent tumor. This case emphasizes the importance 
of timely establishment of initial diagnosis, early metastasis 
in treatment responsive patients and under-utilization of posi-
tron emission tomography-computed tomography (PET-CT) 
during the treatment to detect sub-clinical metastasis.
Introduction
Ewing's sarcoma (ES) is the second most common bone 
tumor after osteosarcoma in children and adolescents. ES 
are aggressive tumors with a tendency towards recurrence 
following resection and pronounced proclivity toward early 
hematogenous metastases to lungs and bone. No hereditary or 
congenital syndromes, environmental or known risk factors 
have been associated with the occurrence of ES. In 90% of 
cases, Ewing's sarcoma family tumor (ESFT) cells harbor the 
translocation t(11;22)(q24;q12), and in the remaining 10% the 
variant translocation is t(21;12)(22;12) (1,2). Although peak 
incidence occurs between the ages of 10 and 20 years, patients 
of younger or older ages account for almost 30% of the 
cases (3). Poor prognostic factors include tumor ≥8 cm, pelvic 
primary, presence of metastases and age >15 at the time of 
diagnosis (4). Older patients with sarcoma also have a higher 
risk of thromboembolism (5).
Case report
A 52-year-old healthy female presented with a 2-week history 
of pain in her right posterior thigh. The pain originated in the 
patient's right buttock and radiated to the back of the knee 
without a radicular component. Motor strength, sensory func-
tion and reflexes were normal. Musculoskeletal examination 
was within normal limits without tenderness of the hips or back. 
Despite the use of non‑steroidal anti‑inflammatory medi-
cations and physical therapy the pain persisted. On subsequent 
reassessment, a radicular component was present. Magnetic 
resonance imaging (MRI) demonstrated an irregular-shaped 
right presacral mass with heterogeneous short T1 inversion 
recovery (STIR) hyperintensity (Fig. 1A) and T1 hypoin-
tensity (Fig. 1B). Additional evaluation with computed 
tomography (CT) of the pelvis revealed a complex mass with 
central necrosis and a thick enhancing wall extending into the 
right S2 neural foramen with lytic bone destruction (Fig. 1C) 
measuring 6x6x5 cm with compression of the right piriformis 
muscle posteriorly (Fig. 1D). No adenopathy or correlation to 
gynecologic structures of the pelvis were found.
An initial core needle biopsy of the mass revealed a small, 
round blue cell neoplasm, suggestive of a primitive neuroecto-
dermal tumor. The tumor was markedly positive for vimentin 
(Fig. 2A) and CD99 (Fig. 2B). Staging workup with a posi-
tron emission tomography-computed tomography (PET-CT)
image (Fig. 3A) demonstrated a large avid fluorodeoxyglucose 
(FDG) uptake at the level of the lower sacrum measuring 
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approximately 5.8 cm. There was no other area of abnormally 
increased uptake of FDG in the whole body PET-CT. An 
open biopsy revealed a better preserved tumor with identical 
histological features testing positive for the ES translocation 
(22q12), and a diagnosis of ES stage III (T2bN0M0) was made.
The patient was treated with 17 cycles of vincristine 
2 mg/m2, doxorubicine 75 mg/m2, cyclophosphamide 
1200 mg/m2 with mesna rescue alternating with ifosfamide 
1800 mg/m2 and etoposide 100 mg/m2 (IE) as described by 
Grier et al (6). Re-assessment after four cycles demonstrated 
a significant response. The involvement of S1 and S2 nerve 
roots represented a significant surgical challenge. As a result, 
the patient received external beam radiation at a dose of 56 Gy 
followed by 13 additional cycles of adjuvant chemotherapy. 
Post-treatment CT of the pelvis demonstrated a near complete 
resolution of the mass with minimal residual infiltrative soft 
tissue changes within the right presacral space. PET imaging 
demonstrated normalization of FDG uptake within the pelvic 
mass (Fig. 3B). Six weeks post-adjuvant chemotherapy, the 
patient presented with acute shortness of breath. PET-CT 
demonstrated an area of increased FDG uptake within the 
bilateral pulmonary hila, representing interval development of 
metastatic disease. A subsequent biopsy of the lung confirmed 
the diagnosis of metastatic ES. Two weeks later the patient 
succumbed to the disease after opting for comfort care.
Discussion
The mortality rate for ES is extremely high when treated 
with surgery or radiation therapy alone for local control of 
the disease (7). Over the past 5 decades, advances in chemo-
therapy, surgery and radiation therapy have improved the 
  A   B
Figure 1. A lumbar spine MRI shows an irregular shaped right presacral mass (arrow) with (A) heterogeneous STIR hyperintensity and (B) T1 hypointensity. 
(C) CT of the pelvis shows a complex mass (arrow) with central necrosis and a thick enhancing wall extending into the right S2 neural foramen with lytic bone 
destruction. (D) Pelvic CT shows a 6x5x6 cm mass (arrow) compressing the right piriformis muscle posteriorly. CT, computed tomography.
Figure 2. Tissue biopsy revealed a small, round blue cell neoplasm. Immunohistochemistry stains were positive for (A) vimentin and (B) CD99.
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prognosis of patients with ESFTs (8). The limited number of 
patients over the age of 40 and the exclusion of these patients 
from the majority of trials render these findings difficult to 
generalize (9).
Tumors of the pelvis have a poorer prognosis when 
compared with other sites. Whether this is related to the chal-
lenge of achieving local control or the proximity to critical 
deep structures remains to be elucidated. Current treatment 
recommendations are based on the available literature that is 
limited by selection bias, small study size, non-standard radia-
tion therapy technique and lack of randomized trials comparing 
the two management approaches. The role of surgery in 
treating ES is controversial; however, certain studies suggest 
that resection with chemotherapy and irradiation positively 
impacts patient survival (10). Radiotherapy is usually applied 
at doses of 40-45 Gy for microscopic residues and 50-60 Gy 
for macroscopic disease (11). Treatment of adult patients 
follows the same principles. However, tolerability of therapies 
in adults are taken into account when transferring treatment 
protocols conceived for patients under the age of 30 years (11).
Although most cases of ES present as localized 
disease, overt metastases are capable of developing rapidly. 
Microscopic metastatic disease has been postulated to be 
present at the time of presentation. However, its spread is held 
in check by as yet unidentified factors secreted by the primary 
tumor. When the primary tumor is removed or irradiated, 
the loss of the putative suppressive factors may permit the 
metastases to grow. The use of chemotherapy in conjunction 
with surgery or radiation therapy to treat presumed metastatic 
disease has substantially improved survival (12).
Beyond specific clinical trials, patients with metastatic 
disease receive similar therapy to that administered for 
localized disease, with appropriate local treatment of metas-
tases, usually radiotherapy. Certain studies have suggested 
benefit from intensive chemotherapy followed by autologous 
stem cell rescue, but randomized trials have not yet been 
performed and the benefit of stem cell transplant remains 
unproven. Patients with recurrent disease fare poorly, with 
5-year survival rates of less than 20% (11). Current studies 
show that, following achieving remission in patients with 
non-metastatic ES, 30-40% of these patients are likely to 
develop recurrence of local or metastatic disease (13). The 
majority of these studies report a time range of 2-10 years 
between commencing treatment and development of recur-
rence (14). Patients relapsing later than 2 years from initial 
diagnosis have more favorable outcomes (11).
This case report raises the importance of early metas-
tasis in a treatment-responsive patient. According to current 
guidelines, initial work-up for staging in a non-metastatic ES 
is followed by reassessment of treatment response after 3-6 
treatment cycles using focal PET-CT. In treatment responsive 
ES, local therapy is followed by additional chemotherapy. A 
surveillance follow‑up imaging every 2‑3 months for the first 
three years is recommended for localized, non-metastatic 
ES. The current case has demonstrated complex issues with 
localized pelvic ES in an older patient who initially responded 
well to chemo-radiation therapy, with complete resolution 
of the tumor. Despite adequate control of the local disease, 
multimodal therapy did not appear to affect metastasis. 
Although sarcomas are notorious for metastasis into lungs and 
bone, the utility of PET-CT and MRI for detecting subclinical 
recurrence or metastases has not been established during 
the treatment period. Only the primary site is evaluated by 
imaging for treatment response 10-12 weeks in to therapy.
In patients with lung metastases, the resection of residual 
metastases after chemotherapy, and whole lung irradiation, 
may grant a survival advantage (11). Most intensive thera-
pies with additional agents have failed to markedly increase 
long-term survival in patients with metastatic disease. The 
impact of chemotherapy on metastasis of ES patients over the 
age of 30 remains to be elucidated. A recent intergroup study 
suggested that the addition of IE to traditional regimens may 
confer a local control benefit (15). Similar effects, with the 
addition of IE on survival benefit, have also been reported by 
another randomized trial among patients with non-metastatic 
pelvic ES (6).
Figure 3. (A) PET‑CT image at the level of the lower sacrum demonstrated a large avid fluorodeoxyglucose (FDG) uptake within the sacral mass mea-
suring approximately 5.8 cm. (B) Post-treatment PET/CT image shows normalization of FDG uptake within the pelvic mass. PET-CT, positron emission 
tomography-computed tomography.
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At present, patients should be offered participation in a 
clinical trial when available. Barring trial participation, multi-
modality therapy, as described above is recommended.
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